TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
THERMO FISHER SCIENTIFIC INC.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Jul 31, 2026
$679.38−10.62 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $252.05B
- P/E (TTM)
- 36.6
- Dividend yield
- 0.25%
THERMO FISHER SCIENTIFIC INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | $23.98B | $23.16B | $23.04B | – | – | – | – | – | – | – | 53.8% | +3.6% |
| Life Sciences Solutions | $10.37B | $9.63B | $9.98B | $13.53B | $15.63B | $12.17B | $6.86B | $6.27B | $5.73B | $5.32B | 23.3% | +7.7% |
| Analytical Instruments | $7.55B | $7.46B | $7.26B | $6.62B | $6.07B | $5.12B | $5.52B | $5.47B | $4.82B | $3.67B | 17.0% | +1.2% |
| Specialty Diagnostics | $4.68B | $4.51B | $4.41B | $4.76B | $5.66B | $5.34B | $3.72B | $3.72B | $3.49B | $3.34B | 10.5% | +3.6% |
| Laboratory Products and Biopharma Services | – | $23.00B | $22.89B | $22.30B | $14.86B | $12.25B | $10.60B | $10.04B | $7.83B | $6.72B | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences Solutions | $3.77B | $3.50B | $3.42B | $5.58B | $7.82B | $6.11B | $2.45B | $2.16B | $1.89B | $1.60B | +7.6% |
| Laboratory Products and Biopharma Services | $3.35B | $3.09B | $3.36B | – | – | – | – | – | – | – | +8.4% |
| Analytical Instruments | $1.74B | $1.96B | $1.91B | $1.51B | $1.20B | $808.00M | $1.27B | $1.25B | $1.03B | $749.00M | -11.2% |
| Specialty Diagnostics | $1.26B | $1.16B | $1.12B | $1.02B | $1.28B | $1.37B | $930.00M | $952.00M | $927.00M | $910.00M | +8.4% |
| Laboratory Products and Biopharma Services | – | $3.09B | $3.36B | $2.87B | $1.84B | $1.27B | $1.32B | $1.26B | $1.00B | $974.00M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues | $25.97B | $25.03B | $25.24B | $28.55B | $30.36B | $25.31B | $19.50B | $18.87B | $17.37B | $15.71B | 58.3% | +3.7% |
| Consumables | $18.66B | $17.59B | $17.60B | $20.62B | $22.61B | $18.53B | $13.11B | $12.58B | – | – | 41.9% | +6.1% |
| Service revenues | $18.59B | $17.85B | $17.61B | $16.37B | $8.85B | $6.91B | $6.05B | $5.49B | $3.54B | $2.56B | 41.7% | +4.2% |
| Instruments | $7.30B | $7.45B | $7.65B | $7.92B | $7.75B | $6.78B | $6.39B | $6.29B | – | – | 16.4% | -1.9% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $23.03B | $22.50B | $22.76B | $24.59B | $19.66B | $17.08B | $12.90B | $12.14B | – | – | 51.7% | +2.4% |
| Other | $22.32B | $21.12B | $20.84B | – | – | – | – | – | – | – | 50.1% | +5.6% |
| United States | $22.24B | $21.76B | $22.01B | $23.82B | $18.91B | $16.44B | $12.37B | $11.63B | $10.13B | $9.09B | 49.9% | +2.2% |
| Europe | $11.83B | $10.86B | $10.74B | $10.76B | $11.13B | $8.28B | $6.36B | $6.22B | – | – | 26.5% | +8.9% |
| Asia-Pacific | $8.10B | $7.96B | $7.87B | $8.12B | $7.22B | $5.82B | $5.52B | $5.25B | – | – | 18.2% | +1.8% |
| Other regions | $1.60B | $1.56B | $1.48B | $1.44B | $1.20B | $1.03B | $764.00M | $750.00M | – | – | 3.6% | +2.3% |
| United Kingdom | – | – | – | – | – | – | – | – | – | $742.20M | – | – |
| Germany | – | – | – | – | – | – | – | – | – | $995.80M | – | – |
| Japan | – | – | – | – | – | – | – | – | – | $737.30M | – | – |
| China | – | – | – | $3.79B | $3.44B | $2.80B | $2.75B | $2.50B | $2.06B | $1.73B | – | – |
| Other | – | $21.12B | $20.84B | $21.10B | $20.30B | $12.99B | $10.42B | $10.23B | $8.73B | $7.46B | – | – |
From the segment and revenue-disaggregation notes of Thermo Fisher Scientific's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.